title: Quality of life and antihypertensive effect with nebivolol and losartan.
abstract: BACKGROUND
  Quality of life and antihypertensive effect, two important therapeutic goals, were determined with the third generation beta-blocker nebivolol and the angiotensin receptor blocker losartan are compared.
  
  
  METHODS
  In a double-blind, randomized, parallel group study 314 patients with hypertension were treated for 12 weeks with 5 mg of nebivolol or 50 mg of losartan once daily. If after 6 weeks diastolic blood pressure (BP) was not normalized 12.5 mg of hydrochlorothiazide once daily was added. Effects of treatment were compared using analysis of variance.
  
  
  RESULTS
  Both drugs decreased systolic BP similarly. The decrease in diastolic BP was greater (P < .0001) with nebivolol (-12 mm Hg after 6 and 12 weeks) than with losartan (-8 and -10 mm Hg after 6 and 12 weeks, respectively). Quality of life parameters did not differ between the two treatments. This was true after 6 and 12 weeks of treatment and results did not change when corrected for different effects on BP. Aspects of quality of life including questions on sexual function did not differ between the two treatments except for headache occurring less frequently (P < .05) in patients on nebivolol monotherapy at 6 weeks.
  
  
  CONCLUSIONS
  At advocated doses nebivolol and losartan decrease systolic BP similarly, whereas the decrease in diastolic BP was slightly greater with nebivolol. Overall quality of life parameters did not differ between nebivolol and losartan. The effect on sexual function did not differ between the two treatments and less patients had headache with nebivolol than with losartan after 6 weeks of monotherapy.
authors.forename: Luc M
authors.initials: LM
authors.lastname: Van Bortel
authors.forename: Christopher J
authors.initials: CJ
authors.lastname: Bulpitt
authors.forename: Francesco
authors.initials: F
authors.lastname: Fici
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000368:Aged; D000704:Analysis of Variance; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001578:Benzopyrans / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology; D004311:Double-Blind Method; D004983:Ethanolamines / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D019808:Losartan / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D000068577:Nebivolol; D011788:Quality of Life; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000319:Adrenergic beta-Antagonists; D047228:Angiotensin II Type 1 Receptor Blockers; D000959:Antihypertensive Agents; D001578:Benzopyrans; D004983:Ethanolamines; D000068577:Nebivolol; D019808:Losartan